AAM
KRYS icon

Advisors Asset Management’s Krystal Biotech KRYS Stock Holding History

Advisors Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.4K Buy
292
+211
+260% +$56.1K ﹤0.01% 1261
2025
Q4 		$20K Buy
+81
New +$17K ﹤0.01% 1351

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisors Asset Management's KRYS Position: Q1 2026 in Review

Advisors Asset Management increased its Krystal Biotech (KRYS) stake by 260% in Q1 2026, buying an estimated $56.1K and bringing the position to 292 shares worth $75.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1261.

Advisors Asset Management first reported a position in KRYS in Q4 2025 and has held it in 2 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Advisors Asset Management held 292 shares of Krystal Biotech worth $75.4K as of Q1 2026.
  • Advisors Asset Management bought 211 Krystal Biotech shares in Q1 2026, an estimated $56.1K.
  • Krystal Biotech made up ﹤0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1261 holding.
  • Advisors Asset Management first reported a position in Krystal Biotech in Q4 2025 and has held it in 2 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.